c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

Cancer Letters

Volumn 265, Issue 2, 2008, Pages 258-269

  Zeng, Zhao Shi ^a   Weiser, Martin R ^a   Kuntz, Eleanor ^a   Chen, Chin Tung ^a   Khan, Sajid A ^a   Forslund, Ann ^a   Nash, Garrett M ^a   Gimbel, Mark ^a   Yamaguchi, Yuka ^a   Culliford IV, Alfred T ^a   D'Alessio, Matthew ^a   Barany, Francis ^b   Paty, Philip B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

c Met proto oncogene; Colorectal cancer; Gene amplification; Liver metastasis; PCR LDR

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGASE CHAIN REACTION; LIVER; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MET;

EID: 43949111293     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.049     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer Statistics 57 (2007) 43-66
2. Trusolino L., and Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive. Nat. Rev. Cancer 2 (2002) 289-300
3. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
4. Cooper C.S., Park M., Blair D.G., Tainsky M.A., Huebner K., Croce C.M., and Vande Woude G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311 (1984) 29-33
5. Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., and Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA 84 (1987) 6379-6383
6. Ma P.C., Maulik G., Christensen J., and Salgia R. c-Met: structure, functions and potential for herapeutic inhibition. Cancer Metastasis Rev. 22 (2003) 309-325
7. Xiao G.-H., Jeffers M., Bellacosa A., Mitsuuchi Y., Vande Woude G.F., and Testa J.R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. 98 (2001) 247-252
8. Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., Lubensky I., Neumann H.P., Brauch H., Decker J., Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U., Gerrard B., Dean M., Linehan W.M., and Zbar B. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18 (1999) 2343-2350
9. Takeuchi H., Bilchik A., Saha S., Turner R., Wiese D., Tanaka M., Kuo C., Wang H.J., and Hoon D.S. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9 (2003) 1480-1488
10. Kammula U.S., Kuntz E.J., Francone T.D., Zeng Z., Shia J., Landmann R.G., Paty P.B., and Weiser M.R. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248 (2007) 219-228
11. Zeng Z.S., Weiser M.R., D'Alessio D., Grace A., Shia J., and Paty P.B. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin. Exp. Metastasis 21 (2004) 409-417
12. Smolen G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., Kim W.J., Okimoto R.A., Bell D.W., Sgroi D.C., Christensen J.G., Settleman J., and Haber D.A. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. PNAS 103 (2006) 2316-2321
13. Miller C.T., Lin L., Casper A.M., Lim J., Thomas D.G., Orringer M.B., Chang A.C., Chambers A.F., Giordano T.J., Glover T.W., and Beer D.G. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25 (2005) 409-418
14. Zhao X., Weir B.A., LaFramboise T., Lin M., Beroukhim R., Garraway L., Beheshti J., Lee J.C., Naoki K., Richards W.G., Sugarbaker D., Chen F., Rubin M.A., Janne P.A., Girard L., Minna J., Christiani D., Li C., Sellers W.R., and Meyerson M. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65 (2005) 5561-5570
15. Di Renzo M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S., et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1 (1995) 147-154
16. Fujita S., and Sugano K. Expression of c-Met proto-oncogene in primary colorectal cancer and liver metastases. Jpn. J. Clin. Oncol. 27 (1997) 378-383
17. Otte J.M., Schmitz F., Kiehne K., Stechele H.U., Banasiewicz T., Krokowicz P., Nakamura T., Folsch U.R., and Herzig K. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61 (2000) 237-246
18. Mazzone M., and Comoglio P.M. The Met pathway: master switch and drug target in cancer progression. FASEB J. 20 (2006) 1611-1621
19. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., Gibbs J.B., and Pan B.-S. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67 (2007) 2081-2088
20. Engelman J., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J., Lindeman N., Gale C., Zhao X., Christensen J., Kosaka T., Holmes A., Rogers A., Cappuzzo F., Mok T., Lee C., Johnson B., Cantley L., and Jänne P. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
21. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., and Comoglio P.M. Tyrosine kinase receptor indistinguishable from the c-Met protein. Nature 339 (1989) 155-156
22. Nash G.M., Gimbel M., Shia J., Culliford A.T., Nathanson D.R., Ndubuisi M., Yamaguchi Y., Zeng Z.S., Barany F., and Paty P.B. Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer. J. Clin. Oncol. 21 (2003) 3105-3112
23. Leversha M.A. Mapping of genomic clones by fluorescence in situ hybridization. Methods Mol. Biol. 175 (2001) 109-127
24. Illei P.B., Rusch V.W., Zakowski M.F., and Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. 9 (2003) 2108-2113
25. Barany F. Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc. Natl. Acad. Sci. USA 88 (1991) 189-193
26. Nathanson D.R., Culliford A.T.t., Shia J., Chen B., D' Alessio M., Zeng Z.S., Nash G.M., Gerald W., Barany F., and Paty P.B. HER 2/neu expression and gene amplification in colon cancer. Int. J. Cancer 105 (2003) 796-802
27. Rusciano D., Lorenzoni P., and Burger M.M. Expression of constitutively activated hepatocyte growth factor/scatter factor receptor (c-Met) in B16 melanoma cells selected for enhanced liver colonization. Oncogene 11 (1995) 1979-1987
28. Lin S., Rusciano D., Lorenzoni P., Hartmann G., Birchmeier W., Giordano S., Comoglio P., and Burger M.M. C-Met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells. Clin. Exp. Metastasis 16 (1998) 253-265
29. Singh R.K., Tsan R., and Radinsky R. Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis. Clin. Exp. Metastasis 15 (1997) 140-150
30. Herynk M.H., Stoeltzing O., Reinmuth N., Parikh N.U., Abounader R., Laterra J., Radinsky R., Ellis L.M., and Gallick G.E. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res. 63 (2003) 2990-2996
31. Imaizumi Y., Murota H., Kanda S., Hishikawa Y., Koji T., Taguchi T., Tanaka Y., Yamada Y., Ikeda S., Kohno T., Yamamoto K., Mori N., Tomonaga M., and Matsuyama T. Expression of the c-Met proto-oncogene and its possible involvement in liver invasion in adult T-cell leukemia. Clin. Cancer Res. 9 (2003) 181-187
32. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., and Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6 (2004) 61-73
33. Kong-Beltran M., Stamos J., and Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6 (2004) 75-84
34. Kim S.J., Johnson M., Koterba K., Herynk M.H., Uehara H., and Gallick G.E. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin. Cancer Res. 9 (2003) 5161-5170
35. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., Kim Y.H., Pollack J.R., Yanagisawa K., Gazdar A., Minna J.D., Kurie J.M., and Carbone D.P. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65 (2005) 226-235